OA10515A - Utilisation du fumagillol et ses dérivés pour préparer des médicaments destinés à combattre les infections intestinales - Google Patents

Utilisation du fumagillol et ses dérivés pour préparer des médicaments destinés à combattre les infections intestinales Download PDF

Info

Publication number
OA10515A
OA10515A OA70088A OA70088A OA10515A OA 10515 A OA10515 A OA 10515A OA 70088 A OA70088 A OA 70088A OA 70088 A OA70088 A OA 70088A OA 10515 A OA10515 A OA 10515A
Authority
OA
OAPI
Prior art keywords
fumagillol
fumagillin
preparation
ester
patients
Prior art date
Application number
OA70088A
Other languages
English (en)
French (fr)
Inventor
Jean-Michel Molina
Francis Derouin
Original Assignee
Sanofi Sa
Assist Publ Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Assist Publ Hopitaux De Paris filed Critical Sanofi Sa
Publication of OA10515A publication Critical patent/OA10515A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
OA70088A 1995-03-27 1997-09-26 Utilisation du fumagillol et ses dérivés pour préparer des médicaments destinés à combattre les infections intestinales OA10515A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27

Publications (1)

Publication Number Publication Date
OA10515A true OA10515A (fr) 2002-04-24

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
OA70088A OA10515A (fr) 1995-03-27 1997-09-26 Utilisation du fumagillol et ses dérivés pour préparer des médicaments destinés à combattre les infections intestinales

Country Status (25)

Country Link
US (1) US5900431A (es)
EP (1) EP0817626B1 (es)
JP (1) JP3260378B2 (es)
KR (1) KR100286920B1 (es)
CN (1) CN1072485C (es)
AP (1) AP646A (es)
AT (1) ATE172641T1 (es)
AU (1) AU706161B2 (es)
CA (1) CA2216623C (es)
CZ (1) CZ286821B6 (es)
DE (1) DE69600879T2 (es)
DK (1) DK0817626T3 (es)
EA (1) EA000150B1 (es)
ES (1) ES2128846T3 (es)
FR (1) FR06C0014I2 (es)
HU (1) HU224028B1 (es)
IS (1) IS2048B (es)
NO (1) NO315968B1 (es)
NZ (1) NZ304906A (es)
OA (1) OA10515A (es)
PL (1) PL183378B1 (es)
SK (1) SK283883B6 (es)
TR (1) TR199701048T1 (es)
UA (1) UA41446C2 (es)
WO (1) WO1996030010A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2216623C (en) * 1995-03-27 2005-05-31 Sanofi Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
DE60034770T2 (de) 1999-02-26 2008-04-30 Sanofi-Aventis Stabile fumagillin-formulierung
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
MX2010005857A (es) * 2007-11-28 2010-11-22 Mersana Therapeutics Inc Conjugados de analogos de fumagillina biodegradables biocompatibles.
EP2317845A4 (en) * 2008-07-18 2011-11-09 Zafgen Inc METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
JP5890312B2 (ja) 2009-10-09 2016-03-22 ザフゲン，インコーポレイテッド 肥満治療に用いられるスルホン化合物
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
MX343135B (es) 2010-01-08 2016-10-25 Zafgen Corp * Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
EP2595988B1 (en) 2010-07-22 2014-12-17 Zafgen, Inc. Tricyclic compounds and methds of making and using same
CA2817199C (en) 2010-11-09 2019-01-15 Zafgen, Inc. Crystalline solids of a metap-2 inhibitor and methods of making and using same
EP2646016B1 (en) 2010-11-29 2017-05-17 Zafgen, Inc. Treatment if obesity using non-daily administration of 6-0-(4-dimethylaminoethoxy)cinnamoyl fumagillol
JP6058557B2 (ja) 2011-01-26 2017-01-11 ザフゲン，インコーポレイテッド テトラゾール化合物ならびにその作製方法および使用方法
EP2683706B1 (en) 2011-03-08 2018-02-21 Zafgen, Inc. Oxaspiro [2.5]octane derivatives and analogs
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
KR101979039B1 (ko) 2011-05-06 2019-05-15 자프겐 인크. 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
CN104169268A (zh) 2012-01-18 2014-11-26 扎夫根股份有限公司 三环砜化合物及其制备和使用方法
US9359369B2 (en) 2012-01-18 2016-06-07 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
WO2013169727A1 (en) 2012-05-07 2013-11-14 Zafgen, Inc. Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same
JP2015516426A (ja) 2012-05-08 2015-06-11 ザフゲン，インコーポレイテッド ＭｅｔＡＰ２阻害剤による視床下部性肥満症の治療
US9573918B2 (en) 2012-05-09 2017-02-21 Zafgen, Inc. Fumigillol compounds and methods of making and using same
BR112015010196A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc métodos de tratar doença do fígado
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
KR20150080614A (ko) 2012-11-05 2015-07-09 자프겐 인크. 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물
WO2014152861A2 (en) 2013-03-14 2014-09-25 Zafgen, Inc. Methods of treating renal disease and other disorders
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
WO1992002240A2 (en) * 1990-07-27 1992-02-20 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5328930A (en) * 1993-03-01 1994-07-12 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin
CA2216623C (en) * 1995-03-27 2005-05-31 Sanofi Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Also Published As

Publication number Publication date
EA199700267A1 (ru) 1998-04-30
CZ304997A3 (en) 1997-12-17
DE69600879T2 (de) 1999-06-02
JPH11506421A (ja) 1999-06-08
NO974466L (no) 1997-09-26
AP646A (en) 1998-04-27
NO974466D0 (no) 1997-09-26
NZ304906A (en) 1999-06-29
IS4557A (is) 1997-09-11
AP9701092A0 (en) 1997-10-31
EP0817626A2 (fr) 1998-01-14
TR199701048T1 (xx) 1998-01-21
AU706161B2 (en) 1999-06-10
CN1072485C (zh) 2001-10-10
WO1996030010A2 (fr) 1996-10-03
UA41446C2 (uk) 2001-09-17
EA000150B1 (ru) 1998-10-29
AU5278696A (en) 1996-10-16
KR19980703271A (ko) 1998-10-15
IS2048B (is) 2005-09-15
HUP9801220A2 (hu) 1999-09-28
ES2128846T3 (es) 1999-05-16
SK283883B6 (sk) 2004-04-06
PL183378B1 (pl) 2002-06-28
DE69600879D1 (de) 1998-12-03
CZ286821B6 (en) 2000-07-12
HUP9801220A3 (en) 2001-10-29
PL322470A1 (en) 1998-02-02
SK130797A3 (en) 1998-03-04
FR06C0014I1 (es) 2006-11-17
FR06C0014I2 (es) 2006-12-29
WO1996030010A3 (fr) 1996-11-28
MX9707150A (es) 1998-07-31
US5900431A (en) 1999-05-04
HU224028B1 (hu) 2005-05-30
ATE172641T1 (de) 1998-11-15
CA2216623A1 (en) 1996-10-03
CN1179715A (zh) 1998-04-22
EP0817626B1 (fr) 1998-10-28
DK0817626T3 (da) 1999-07-12
JP3260378B2 (ja) 2002-02-25
CA2216623C (en) 2005-05-31
NO315968B1 (no) 2003-11-24
KR100286920B1 (ko) 2001-04-16

Similar Documents

Publication Publication Date Title
EP0817626B1 (fr) Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales
EP0385846B1 (fr) Composition pharmaceutique à libération prolongée d'acide valproîque
FR2774591A1 (fr) Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
EP0237538B1 (fr) Preparation d'un medicament retard
EP0437128B1 (fr) Utilisation des dérivés des fluoroquinolones pour le traitement de la pneumonie à Pneumocystis carinii
JPH0232093A (ja) 抗レトロウィルスジフルオロ化ヌクレオシド類
US4880742A (en) Prostaglandin biosynthesis inhibitors
KR20000057628A (ko) 당뇨병환자의 혈관 기능부전 예방을 위한 약제 제조에 있어서카테콜-오-메틸전이효소 억제제의 용도
WO1991007960A1 (fr) Compositions pharmaceutiques destinees au traitement de l'ataxie et les troubles de l'equilibre
BE1004857A3 (fr) Complexes de l'acide polyadenylique avec l'acide polyuridylique.
EP0555302A1 (en) Method of treating demyelinating disease
CH678275A5 (es)
FR2566664A1 (fr) Composition utile au traitement de la diarrhee contenant du dextromethorphan
EA007488B1 (ru) Фармацевтические композиции с контролируемым высвобождением, содержащие альгинат натрия и альгинат натрия-кальция
FR2618676A1 (fr) Compositions pharmaceutiques antivirales
FR2585573A1 (fr) Medicament pour prevenir l'abus d'alcool
CH679982A5 (en) Anti-retroviral compsn. contg. 2-methyl-9-hydroxy-ellipticine acetate - esp. for treatment or prevention of AIDS with greater activity than AZT
EP0818997A1 (fr) Compositions comprenant l'amiodarone et le betaxolol
FR2684297A1 (fr) Utilisation d'un acide amine soufre pour la preparation d'un medicament destine au traitement de l'eczema.
JPH02275822A (ja) 語音聴力改善剤
FR2527077A1 (fr) Nouveau medicament a base d'un anti-depresseur et d'un alcaloide ergopeptidique